• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Yale Medical Group adopts conflicts-of-interest policy

Yale Medical Group adopts conflicts-of-interest policy

September 27, 2010
CenterWatch Staff

Yale Medical Group, affiliated with Yale University’s medical school, has adopted a new conflicts-of-interest policy to regulate relationships between its doctor-academics and industry, Pharmalot reported. The new policy comes on the heels of a similar move at Harvard Medical School, and after a handful of other academic medical centers have reviewed their own rules. Yale Medical’s new regulations attempt to tread a fine line, designed to fend off accusations that industry money and relationships unduly influence its doctors without cutting pharma out of the equation completely. It addresses financial ties to drug and device makers; gifts, meals and other goodies from industry; ghostwriting; samples; consulting and continuing medical education. According to Pharmalot, drug sales reps bear the brunt of the rules; they’ll be allowed to visit only by invitation and with an appointment. Companies can still sponsor CME programs and provide meals during CME events. “We wanted to upgrade the guidelines to a full-blown policy so that faculty and others understand that these are no longer electives, because the landscape has changed,” CEO David Leffell said. The Yale Medical Group is staffed by roughly 800 academic physicians from the Yale School of Medicine; it is not a separate practice or foundation. The move reflects ongoing debate over the interactions between academics and drug and device makers. The National Institutes of Health has proposed new conflict rules for researchers. “Our view is that we continue to respect the role the pharmaceutical industry plays in contributing to and investing in the health of people,” Leffell said.

Upcoming Events

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

  • 25May

    How Can the Accelerated Availability of Pfizer-BioNTech’s COVID-19 Vaccine be Replicated?

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing